中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
6期
650-652
,共3页
心力衰竭,充血性%芪苈强心胶囊%培哚普利
心力衰竭,充血性%芪藶彊心膠囊%培哚普利
심력쇠갈,충혈성%기력강심효낭%배타보리
Heart failure,congestive%Qiliqiangxin capsule%Perindopril
目的 观察芪苈强心胶囊联合培哚普利治疗充血性心力衰竭(CHF)的临床疗效.方法 59例CHF患者完全随机分为研究组(29例)和对照组(30例),均给予内科常规抗心力衰竭治疗.对照组加服培哚普利,初始剂量2 mg,1次/d,逐渐加至靶剂量4 mg,1次/d;研究组在对照组的基础上口服芪苈强心胶囊1.2 g/次,3次/d,治疗12周.观察2组左心室射血分数(LVEF)、左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)、每搏输出量、心排血量以及心功能变化.结果 研究组治疗后LVEF[(46.89±8.11)%]、LVEDV[(129.20+25.13)ml/m2]、LVESV[(70.90±32.07)ml/m2]、心排血量[(4.32±0.65)L/min]、每搏输出量[(55.06±13.27)ml]较治疗前[分别为(29.60±11.01)%、(164.40±31.02)ml/m2、(95.60±33.12)m]/m2、(2.91±0.56)L/min、(37.69±13.62)ml]均有明显改善,差异有统计学意义(P<0.05或P<0.01);LVEF、LVEDV、LVESV、心排血量、每搏输出量均明显高于对照组治疗后[分别为(34.70±9.00)%、(148.20.4-29.31)ml/m2、(81.10±31.21)ml/m2、(3.14±0.60)L/min、(49.56±14.29)ml,P<0.05或P<0.01].研究组总有效率为93.1%(27/29),与对照组的66.7%(20/30)比较,差异有统计学意义(P<0.01).2组均未发现明显不良反应.结论 芪苈强心胶囊联合培哚普利治疗CHF疗效较好,不良反应较少,是较为安全有效的方法.
目的 觀察芪藶彊心膠囊聯閤培哚普利治療充血性心力衰竭(CHF)的臨床療效.方法 59例CHF患者完全隨機分為研究組(29例)和對照組(30例),均給予內科常規抗心力衰竭治療.對照組加服培哚普利,初始劑量2 mg,1次/d,逐漸加至靶劑量4 mg,1次/d;研究組在對照組的基礎上口服芪藶彊心膠囊1.2 g/次,3次/d,治療12週.觀察2組左心室射血分數(LVEF)、左心室舒張末期容積(LVEDV)、左心室收縮末期容積(LVESV)、每搏輸齣量、心排血量以及心功能變化.結果 研究組治療後LVEF[(46.89±8.11)%]、LVEDV[(129.20+25.13)ml/m2]、LVESV[(70.90±32.07)ml/m2]、心排血量[(4.32±0.65)L/min]、每搏輸齣量[(55.06±13.27)ml]較治療前[分彆為(29.60±11.01)%、(164.40±31.02)ml/m2、(95.60±33.12)m]/m2、(2.91±0.56)L/min、(37.69±13.62)ml]均有明顯改善,差異有統計學意義(P<0.05或P<0.01);LVEF、LVEDV、LVESV、心排血量、每搏輸齣量均明顯高于對照組治療後[分彆為(34.70±9.00)%、(148.20.4-29.31)ml/m2、(81.10±31.21)ml/m2、(3.14±0.60)L/min、(49.56±14.29)ml,P<0.05或P<0.01].研究組總有效率為93.1%(27/29),與對照組的66.7%(20/30)比較,差異有統計學意義(P<0.01).2組均未髮現明顯不良反應.結論 芪藶彊心膠囊聯閤培哚普利治療CHF療效較好,不良反應較少,是較為安全有效的方法.
목적 관찰기력강심효낭연합배타보리치료충혈성심력쇠갈(CHF)적림상료효.방법 59례CHF환자완전수궤분위연구조(29례)화대조조(30례),균급여내과상규항심력쇠갈치료.대조조가복배타보리,초시제량2 mg,1차/d,축점가지파제량4 mg,1차/d;연구조재대조조적기출상구복기력강심효낭1.2 g/차,3차/d,치료12주.관찰2조좌심실사혈분수(LVEF)、좌심실서장말기용적(LVEDV)、좌심실수축말기용적(LVESV)、매박수출량、심배혈량이급심공능변화.결과 연구조치료후LVEF[(46.89±8.11)%]、LVEDV[(129.20+25.13)ml/m2]、LVESV[(70.90±32.07)ml/m2]、심배혈량[(4.32±0.65)L/min]、매박수출량[(55.06±13.27)ml]교치료전[분별위(29.60±11.01)%、(164.40±31.02)ml/m2、(95.60±33.12)m]/m2、(2.91±0.56)L/min、(37.69±13.62)ml]균유명현개선,차이유통계학의의(P<0.05혹P<0.01);LVEF、LVEDV、LVESV、심배혈량、매박수출량균명현고우대조조치료후[분별위(34.70±9.00)%、(148.20.4-29.31)ml/m2、(81.10±31.21)ml/m2、(3.14±0.60)L/min、(49.56±14.29)ml,P<0.05혹P<0.01].연구조총유효솔위93.1%(27/29),여대조조적66.7%(20/30)비교,차이유통계학의의(P<0.01).2조균미발현명현불량반응.결론 기력강심효낭연합배타보리치료CHF료효교호,불량반응교소,시교위안전유효적방법.
Objective To investigate the clinic effect of Qiliqiangxin capsule combined perindopril on congestive heart failure(CHF). Methods Totally 59 patients with CHF were randomly divided into the experimental group and control group. All patients were given conventional medical treatment. The control group was given perindopril , which increased from 2 mg once a day to 4 mg once a day gradually. Experimental group was given Qiliqiangxin capsule 1.2 g orally three times a day for 12 weeks. The changes of left ventricular ejection fraction( LVEF) , left ventricular end of diastolic volume( LVEDV) ,left ventricular end of systolic volume (LVESV) , stroke volume (SV) , cardiac output (CO) and cardiac function (NYHA) were observed. Results Before the treatment, the LVEF was (29.60 ±11.01)%, LVEDV was (129. 20 ±25.13)ml/m2, LVESV was (95. 60 ±33.12 ml/m2) , cardiac output was (2. 91 ± 0. 56) L/min, stroke volume was ( 37. 69 ± 13. 62) ml. After the treatment, the LVEF was (46. 89 ±8.11)%, LVEDV was (164.40 ±31. 02)ml/m2, LVESV was(70.90 ±32.07)ml/m2, cardiac output was (4.32 ±0.65)L/min and stroke volume was(55.06 ±13.27) ml. There was an earlier improvement of LVEF, LVEDV, LVESV cardiac output and stroke volume after treatment. Meanwhile, after the treatment the LVEF was (34.70 ±9.00)%, LVEDV was (148.20 ±29.31)ml/m2, LVESV was (81. 10 ±31.21)ml/m2, cardiac output was (3.14 ±0.60) L/min and stroke volume was (49.56 ±14.29)ml in the control group. The difference of total effective rate between the experimental group (93. 1% ) and the control group (66.7%) was also significant ( P< 0.01). Side application were not found in the two groups. Conclusion The application of Qiliqiangxin capsule combined with perindopril in treating congestive heart failure is safe and effective.
